I wish that article also exposed the fact that the FDA limited our CD12 to only 2 (two) doses -- while the success of many of our eIND patients was attributable to 3 or 4 doses.

All we have to do is listen to Dr.NP's recent story about his friend's family member who finally turned around after the 3rd dose to understand how the CD12 has been handicapped -- and how that trial might have been terminated due to overwhelming efficacy at maybe the 50% interim had we been allowed to administer the proper dosage.

Assuming we have a favorable outcome in January, the survival numbers exposed to the world will be lower than they should be, and people will not fully understand just how powerful leronlimab really is.